Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Globally, NAFLD is one of the most common liver disorders, with an estimated prevalence rate of more than 30% in men and 15% in women and an even higher prevalence in people with type 2 diabetes mellitus. Optimal pharmacologic therapeutic approaches for NAFLD are an urgent necessity. In this study, we showed that compared with healthy controls, hepatic ACSL4 levels in patients with NAFLD were found to be elevated. Suppression of ACSL4 expression promoted mitochondrial respiration, thereby enhancing the capacity of hepatocytes to mediate β-oxidation of fatty acids and to minimize lipid accumulation by up-regulating peroxisome proliferator-activated receptor coactivator-1 alpha. Moreover, we found that abemaciclib is a potent and selective ACSL4 inhibitor, and low dose of abemaciclib significantly ameliorated most of the NAFLD symptoms in multiple NAFLD mice models. Therefore, inhibition of ACSL4 is a potential alternative therapeutic approach for NAFLD. © 2021 by the American Association for the Study of Liver Diseases.

Citation

Jingjing Duan, Zhuo Wang, Ran Duan, Chenxinhui Yang, Ruolin Zhao, Qi Feng, Yuanyuan Qin, Jingwei Jiang, Shouyong Gu, Kaiyan Lv, Libo Zhang, Bixia He, Lutz Birnbaumer, Song Yang, Zhen Chen, Yong Yang. Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice. Hepatology (Baltimore, Md.). 2022 Jan;75(1):140-153

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 34510514

View Full Text